Parkinson Disease Management
On this page
Direct answer
Levodopa combined with carbidopa — typically 100/25 mg three times daily, titrated to response — remains the most effective symptomatic drug for Parkinson disease and the standard for patients above about 70 years, while younger patients often start on a dopamine agonist (pramipexole or ropinirole) or rasagiline to defer motor complications. Long-term levodopa brings wearing-off, dyskinesia and on-off phenomena, managed by dose fractionation, adding entacapone or a longer-acting formulation, or amantadine for dyskinesia — and advanced fluctuations qualify for deep brain stimulation of the subthalamic nucleus, which helps symptoms but not the non-motor progression. Physical therapy, falls prevention and swallowing assessment accompany every prescription, and drug-induced parkinsonism (metoclopramide, haloperidol, some calcium-channel blockers) must be excluded before any of it begins.
What you must remember
- Clinical triad: bradykinesia (mandatory) plus rest tremor (4-6 Hz pill-rolling) and lead-pipe rigidity, with postural instability appearing late — asymmetry and levodopa responsiveness support the diagnosis.
- Levodopa craft: carbidopa (peripheral dopa-decarboxylase inhibitor, at least 75-100 mg daily) prevents peripheral conversion and nausea; take doses away from protein-rich meals because amino acids compete for absorption.
- Young-onset strategy: below about 60-70 years, start with rasagiline (MAO-B inhibitor), amantadine, or a dopamine agonist; agonists delay levodopa complications but carry impulse-control disorders (gambling, hypersexuality) and somnolence.
- Motor-complication toolkit: wearing-off — shorten intervals, add entacapone 200 mg with each dose or switch to extended-release forms; dyskinesia — amantadine; severe unpredictable swings — apomorphine pen or deep brain stimulation.
- Non-motor audit: constipation (treat early), orthostatic hypotension, depression, REM-sleep behaviour disorder, dementia and psychosis — psychosis is treated by reducing antiparkinsonian drugs, adding quetiapine or clozapine, never typical antipsychotics.
- The forbidden list: metoclopramide, haloperidol, and other dopamine blockers worsen parkinsonism; tetrabenazine and valproate in excess also aggravate.
- Surgery criteria: disabling motor fluctuations or dyskinesia despite optimised medical therapy, preserved levodopa responsiveness, and intact cognition — subthalamic nucleus stimulation is the usual target.
- Red flags against idiopathic Parkinson disease: early falls, symmetrical onset, absent tremor, poor levodopa response, early autonomic failure or vertical gaze palsy — pointing instead to progressive supranuclear palsy or multiple system atrophy.
How to work through a treatment course
A 62-year-old retired teacher notices a right-hand tremor and smaller handwriting; examination shows asymmetric rigidity, a pill-rolling rest tremor and slow finger tapping. Idiopathic Parkinson disease is the working diagnosis after drug history and MRI exclude mimics, and because he is 62 and still working, therapy starts conservatively — rasagiline 1 mg daily, with exercise-based physiotherapy and constipation management — buying time before levodopa without letting disability accumulate. Eighteen months later his gait has slowed enough to threaten his job, so levodopa-carbidopa 100/25 three times daily begins, dosed an hour before his protein-heavy lunch, and the response is dramatic: handwriting returns, tremor fades, and he learns the first lesson of levodopa — it works.
Four years on, the trade-offs arrive: benefit lasting three hours instead of five (wearing-off) and writhing peak-dose movements in his arms (dyskinesia). The sequence of rescue: fractionate doses to five smaller ones, add entacapone, introduce amantadine for the dyskinesia, and reassess — with deep brain stimulation counselled once fluctuations become unpredictable despite all of the above, provided his cognition remains intact. Alongside the pharmacology run the quiet determinants of his survival: physiotherapy for gait, home modification against falls, swallow assessment when choking begins, and carer support as the non-motor burden grows — because the drugs treat the motor system, while the disease lives in the whole patient.
How the FMGE frames it
The examiner's discriminators are clinical and pharmacological in equal measure. Clinically: asymmetric pill-rolling tremor with bradykinesia and a good levodopa response equals idiopathic disease, while early falls with vertical gaze palsy equal progressive supranuclear palsy — the mimic MCQ that recurs. Pharmacologically: why carbidopa accompanies levodopa (peripheral decarboxylase inhibition), why the dose avoids protein meals, which drug treats dyskinesia (amantadine) versus wearing-off (entacapone, dose fractionation), and which antipsychotic is acceptable in parkinsonian psychosis (quetiapine or clozapine, never haloperidol). Drug-induced parkinsonism from metoclopramide is the safety-flavoured one-liner. Indian framing adds cost realism — levodopa remains the district-practice workhorse — and the classic anticholinergic cautions: trihexyphenidyl helps tremor in young patients but confuses the elderly.
Frequently asked questions
Why is carbidopa combined with levodopa?
Carbidopa inhibits peripheral dopa-decarboxylase, preventing levodopa's conversion to dopamine outside the brain, increasing central delivery and reducing nausea and hypotension.
Which drug class is preferred first in young-onset Parkinson disease?
Dopamine agonists (pramipexole, ropinirole) or rasagiline to defer levodopa-related motor complications, accepting impulse-control and somnolence risks.
How are wearing-off phenomena managed?
Shorten dosing intervals, add entacapone to each levodopa dose, use extended-release formulations, or move to infusion or surgical options in advanced disease.
Which drugs are contraindicated in parkinsonian psychosis?
Typical antipsychotics such as haloperidol and antiemetics like metoclopramide — quetiapine or clozapine are the accepted choices after reducing antiparkinsonian polypharmacy.
What are the selection criteria for deep brain stimulation?
Disabling motor fluctuations or dyskinesia despite optimised medical therapy, sustained levodopa responsiveness, and preserved cognition, typically with subthalamic nucleus targeting.